Dipraglurant for Dyskinesia, Drug-Induced

Phase-Based Progress Estimates
Dyskinesia, Drug-Induced+2 More
Dipraglurant - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it's effective and safe for treating dyskinesia in Parkinson's patients. The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale.

Eligible Conditions
  • Dyskinesia, Drug-Induced
  • Parkinson Disease
  • Asterixis

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline (Day 1) to Week 12

Week 12
Change from baseline in OFF time based on a standardized PD diary
Change from baseline in ON time without troublesome dyskinesia based on a standardized PD diary
Change from baseline on the Unified Dyskinesia Rating Scale (UDysRS) total score

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Dipraglurant TID
1 of 2
Placebo TID
1 of 2

Experimental Treatment

Non-Treatment Group

140 Total Participants · 2 Treatment Groups

Primary Treatment: Dipraglurant · Has Placebo Group · Phase 2 & 3

Dipraglurant TID
Experimental Group · 1 Intervention: Dipraglurant · Intervention Types: Drug
Placebo TID
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (day 1) to week 12

Who is running the clinical trial?

Addex Pharma S.A.Lead Sponsor
7 Previous Clinical Trials
1,018 Total Patients Enrolled
1 Trials studying Dyskinesia, Drug-Induced
140 Patients Enrolled for Dyskinesia, Drug-Induced

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have PD and you meet the criteria for ON time with troublesome dyskinesia based on a standard PD home diary.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.